Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-...
August 24, 2017
MaxCyte, Inc. - First Day of Dealings on AIM
March 30, 2016
Apellis Pharmaceuticals Announces Pricing of Initial Public Offering
November 8, 2017
Cytox Congratulates Professor John Hardy, First UK Winner of $3m Breakthrough Prize in Life Sciences
November 11, 2015
Oxford, United Kingdom - Cytox congratulates Professor John Hardy (UCL Institute of Neurology, London) on receiving the $3 million (Ł2 million) Breakthrough Prize in Life Sciences for his pioneering research into the genetic causes of Alzheimers disease, other forms of dementia and Parkinsons disease. The Breakthrough Prize in Life Sciences honours transformative advances toward understanding living systems and extending human life. This is the first time that the prize has been awarded to a UK researcher.
We are proud to be associated with John Hardy, commented Richard Pither, CEO Cytox Ltd, He is a much valued member of our Scientific Advisory Panel, and is a key part of the consortium we lead that was awarded Innovate UK funding earlier this year to investigate the application of SNP profiling to risk stratification in Alzheimers disease.
The Breakthrough Prize is backed by Facebook chief executive Mark Zuckerberg and Google co-founder Sergey Brin, among others.